1
|
Czarnowski P, Bałabas A, Kułaga Z, Kulecka M, Goryca K, Pyśniak K, Unrug-Bielawska K, Kluska A, Bagińska-Drabiuk K, Głowienka-Stodolak M, Piątkowska M, Dąbrowska M, Żeber-Lubecka N, Wierzbicka-Rucińska A, Kotowska A, Więckowski S, Mikula M, Kapuśniak J, Socha P, Ostrowski J. Effects of Soluble Dextrin Fiber from Potato Starch on Body Weight and Associated Gut Dysbiosis Are Evident in Western Diet-Fed Mice but Not in Overweight/Obese Children. Nutrients 2024; 16:917. [PMID: 38612951 PMCID: PMC11013109 DOI: 10.3390/nu16070917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 03/14/2024] [Accepted: 03/15/2024] [Indexed: 04/14/2024] Open
Abstract
BACKGROUND The study investigated the impact of starch degradation products (SDexF) as prebiotics on obesity management in mice and overweight/obese children. METHODS A total of 48 mice on a normal diet (ND) and 48 on a Western diet (WD) were divided into subgroups with or without 5% SDexF supplementation for 28 weeks. In a human study, 100 overweight/obese children were randomly assigned to prebiotic and control groups, consuming fruit and vegetable mousse with or without 10 g of SDexF for 24 weeks. Stool samples were analyzed for microbiota using 16S rRNA gene sequencing, and short-chain fatty acids (SCFA) and amino acids (AA) were assessed. RESULTS Results showed SDexF slowed weight gain in female mice on both diets but only temporarily in males. It altered bacterial diversity and specific taxa abundances in mouse feces. In humans, SDexF did not influence weight loss or gut microbiota composition, showing minimal changes in individual taxa. The anti-obesity effect observed in mice with WD-induced obesity was not replicated in children undergoing a weight-loss program. CONCLUSIONS SDexF exhibited sex-specific effects in mice but did not impact weight loss or microbiota composition in overweight/obese children.
Collapse
Affiliation(s)
- Paweł Czarnowski
- Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (P.C.); (A.B.); (M.K.); (K.G.); (K.P.); (K.U.-B.); (A.K.); (K.B.-D.); (M.G.-S.); (M.P.); (M.D.); (N.Ż.-L.); (M.M.)
- Department of Biochemistry, Radioimmunology and Experimental Medicine, Children’s Memorial Health Institute, 04-730 Warsaw, Poland;
| | - Aneta Bałabas
- Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (P.C.); (A.B.); (M.K.); (K.G.); (K.P.); (K.U.-B.); (A.K.); (K.B.-D.); (M.G.-S.); (M.P.); (M.D.); (N.Ż.-L.); (M.M.)
| | - Zbigniew Kułaga
- Public Health Department, Children’s Memorial Health Institute, 04-730 Warsaw, Poland; (Z.K.); (A.K.)
| | - Maria Kulecka
- Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (P.C.); (A.B.); (M.K.); (K.G.); (K.P.); (K.U.-B.); (A.K.); (K.B.-D.); (M.G.-S.); (M.P.); (M.D.); (N.Ż.-L.); (M.M.)
- Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, 02-781 Warsaw, Poland
| | - Krzysztof Goryca
- Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (P.C.); (A.B.); (M.K.); (K.G.); (K.P.); (K.U.-B.); (A.K.); (K.B.-D.); (M.G.-S.); (M.P.); (M.D.); (N.Ż.-L.); (M.M.)
- Genomic Core Facility, Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland
| | - Kazimiera Pyśniak
- Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (P.C.); (A.B.); (M.K.); (K.G.); (K.P.); (K.U.-B.); (A.K.); (K.B.-D.); (M.G.-S.); (M.P.); (M.D.); (N.Ż.-L.); (M.M.)
| | - Katarzyna Unrug-Bielawska
- Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (P.C.); (A.B.); (M.K.); (K.G.); (K.P.); (K.U.-B.); (A.K.); (K.B.-D.); (M.G.-S.); (M.P.); (M.D.); (N.Ż.-L.); (M.M.)
| | - Anna Kluska
- Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (P.C.); (A.B.); (M.K.); (K.G.); (K.P.); (K.U.-B.); (A.K.); (K.B.-D.); (M.G.-S.); (M.P.); (M.D.); (N.Ż.-L.); (M.M.)
| | - Katarzyna Bagińska-Drabiuk
- Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (P.C.); (A.B.); (M.K.); (K.G.); (K.P.); (K.U.-B.); (A.K.); (K.B.-D.); (M.G.-S.); (M.P.); (M.D.); (N.Ż.-L.); (M.M.)
| | - Maria Głowienka-Stodolak
- Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (P.C.); (A.B.); (M.K.); (K.G.); (K.P.); (K.U.-B.); (A.K.); (K.B.-D.); (M.G.-S.); (M.P.); (M.D.); (N.Ż.-L.); (M.M.)
| | - Magdalena Piątkowska
- Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (P.C.); (A.B.); (M.K.); (K.G.); (K.P.); (K.U.-B.); (A.K.); (K.B.-D.); (M.G.-S.); (M.P.); (M.D.); (N.Ż.-L.); (M.M.)
| | - Michalina Dąbrowska
- Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (P.C.); (A.B.); (M.K.); (K.G.); (K.P.); (K.U.-B.); (A.K.); (K.B.-D.); (M.G.-S.); (M.P.); (M.D.); (N.Ż.-L.); (M.M.)
| | - Natalia Żeber-Lubecka
- Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (P.C.); (A.B.); (M.K.); (K.G.); (K.P.); (K.U.-B.); (A.K.); (K.B.-D.); (M.G.-S.); (M.P.); (M.D.); (N.Ż.-L.); (M.M.)
- Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, 02-781 Warsaw, Poland
| | - Aldona Wierzbicka-Rucińska
- Department of Biochemistry, Radioimmunology and Experimental Medicine, Children’s Memorial Health Institute, 04-730 Warsaw, Poland;
| | - Aneta Kotowska
- Public Health Department, Children’s Memorial Health Institute, 04-730 Warsaw, Poland; (Z.K.); (A.K.)
| | - Sebastian Więckowski
- Department of Gastroenterology, Hepatology and Eating Disorders, Children’s Memorial Health Institute, 04-730 Warsaw, Poland; (S.W.); (P.S.)
| | - Michał Mikula
- Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (P.C.); (A.B.); (M.K.); (K.G.); (K.P.); (K.U.-B.); (A.K.); (K.B.-D.); (M.G.-S.); (M.P.); (M.D.); (N.Ż.-L.); (M.M.)
| | - Janusz Kapuśniak
- Department of Dietetics and Food Studies, Faculty of Science and Technology, Jan Dlugosz University, 42-200 Czestochowa, Poland;
| | - Piotr Socha
- Department of Gastroenterology, Hepatology and Eating Disorders, Children’s Memorial Health Institute, 04-730 Warsaw, Poland; (S.W.); (P.S.)
| | - Jerzy Ostrowski
- Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (P.C.); (A.B.); (M.K.); (K.G.); (K.P.); (K.U.-B.); (A.K.); (K.B.-D.); (M.G.-S.); (M.P.); (M.D.); (N.Ż.-L.); (M.M.)
- Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, 02-781 Warsaw, Poland
| |
Collapse
|
2
|
Abstract
Oral bacteria spreading through the body have been associated with a number of systemic diseases. The gut is no exception. Studies in animals and man have indicated that oral bacteria can translocate to the gut and change its microbiota and possibly immune defense. The ectopic displacement of oral bacteria particularly occurs in severe systemic diseases, but also in patients with “chronic” periodontitis. Thus, Porphyromonas gingivalis, which creates dysbiosis in the subgingival microbiota and immune defense, may also cause dysregulation in the gut. A dysbiotic gut microbiota may cause diseases elsewhere in the body. The fact that “chronic” periodontitis may affect the gut microbiota could imply that consideration might in the future be given to a coordinated approach to the treatment of periodontitis and gastrointestinal disease. This area of investigation, which is in its infancy, may represent another pathway for oral bacteria to cause systemic diseases and deserves more research.
Collapse
Affiliation(s)
- Ingar Olsen
- Department of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway
| | - Kazuhisa Yamazaki
- Research Unit for Oral-Systemic Connection, Division of Oral Science for Health Promotion, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| |
Collapse
|
3
|
Liang M, Schwickart M, Schneider AK, Vainshtein I, Del Nagro C, Standifer N, Roskos LK. Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development. Cytometry B Clin Cytom 2015; 90:117-27. [PMID: 26054054 PMCID: PMC5042057 DOI: 10.1002/cyto.b.21259] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/10/2014] [Revised: 04/20/2015] [Accepted: 05/28/2015] [Indexed: 12/19/2022]
Abstract
Receptor occupancy (RO) assays are designed to quantify the binding of therapeutics to their targets on the cell surface and are frequently used to generate pharmacodynamic (PD) biomarker data in nonclinical and clinical studies of biopharmaceuticals. When combined with the pharmacokinetic (PK) profile, RO data can establish PKPD relationships, which are crucial for informing dose decisions. RO is commonly measured by flow cytometry on fresh blood specimens and is subject to numerous technical and logistical challenges. To ensure that reliable and high quality results are generated from RO assays, careful assay design, key reagent characterization, data normalization/reporting, and thorough planning for implementation are of critical importance during development. In this article, the authors share their experiences and perspectives in these areas and discuss challenges and potential solutions when developing and implementing a flow cytometry‐based RO method in support of biopharmaceutical drug development. © 2015 The Authors Cytometry Part B: Clinical Cytometry Published by Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Meina Liang
- Department of Clinical Pharmacology and DMPK, Medimmune, LLC, Mountain View, California, 94043
| | - Martin Schwickart
- Department of Clinical Pharmacology and DMPK, Medimmune, LLC, Mountain View, California, 94043
| | - Amy K Schneider
- Department of Clinical Pharmacology and DMPK, Medimmune, LLC, Mountain View, California, 94043
| | - Inna Vainshtein
- Department of Clinical Pharmacology and DMPK, Medimmune, LLC, Mountain View, California, 94043
| | - Christopher Del Nagro
- Department of Clinical Pharmacology and DMPK, Medimmune, LLC, Mountain View, California, 94043
| | - Nathan Standifer
- Department of Clinical Pharmacology and DMPK, Medimmune, LLC, Mountain View, California, 94043
| | - Lorin K Roskos
- Department of Clinical Pharmacology and DMPK, Medimmune, LLC, Mountain View, California, 94043
| |
Collapse
|
4
|
Abstract
Bone metabolism is regulated by the action of two skeletal cells: osteoblasts and osteoclasts. This process is controlled by many genetic, hormonal and lifestyle factors, but today more and more studies have allowed us to identify a neuronal regulation system termed 'bone-brain crosstalk', which highlights a direct relationship between bone tissue and the nervous system. The first documentation of an anatomic relationship between nerves and bone was made via a wood cut by Charles Estienne in Paris in 1545. His diagram demonstrated nerves entering and leaving the bones of a skeleton. Later, several studies were conducted on bone innervation and, as of today, many observations on the regulation of bone remodeling by neurons and neuropeptides that reside in the CNS have created a new research field, that is, neuroskeletal research.
Collapse
Affiliation(s)
- Alessia Metozzi
- a 1 Department of Surgery and Translational Medicine, Metabolic Bone Diseases Unit, University of Florence, Largo Palagi 1, 50138 Florence, Italy
| | - Lorenzo Bonamassa
- a 1 Department of Surgery and Translational Medicine, Metabolic Bone Diseases Unit, University of Florence, Largo Palagi 1, 50138 Florence, Italy
| | - Gemma Brandi
- b 2 Public Mental Health system 1-4 of Florence, Florence, Italy
| | - Maria Luisa Brandi
- c 3 Department of Surgery and Translational Medicine, Metabolic Bone Diseases Unit, AOUC Careggi, University of Florence, Largo Palagi 1, 50138 Florence, Italy
| |
Collapse
|